165 related articles for article (PubMed ID: 11261826)
1. P53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers.
Done SJ; Arneson CR; Ozçelik H; Redston M; Andrulis IL
Breast Cancer Res Treat; 2001 Jan; 65(2):111-8. PubMed ID: 11261826
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
[TBL] [Abstract][Full Text] [Related]
3. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast.
Done SJ; Eskandarian S; Bull S; Redston M; Andrulis IL
J Natl Cancer Inst; 2001 May; 93(9):700-4. PubMed ID: 11333292
[TBL] [Abstract][Full Text] [Related]
4. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
5. p53 mutations and expression in breast carcinoma in situ.
Lukas J; Niu N; Press MF
Am J Pathol; 2000 Jan; 156(1):183-91. PubMed ID: 10623666
[TBL] [Abstract][Full Text] [Related]
6. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
7. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
[TBL] [Abstract][Full Text] [Related]
8. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
Pang JB; Savas P; Fellowes AP; Mir Arnau G; Kader T; Vedururu R; Hewitt C; Takano EA; Byrne DJ; Choong DY; Millar EK; Lee CS; O'Toole SA; Lakhani SR; Cummings MC; Mann GB; Campbell IG; Dobrovic A; Loi S; Gorringe KL; Fox SB
Mod Pathol; 2017 Jul; 30(7):952-963. PubMed ID: 28338653
[TBL] [Abstract][Full Text] [Related]
9. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
[TBL] [Abstract][Full Text] [Related]
10. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas.
Zhang GJ; Kimijima I; Abe R; Kanno M; Katagata N; Hara K; Watanabe T; Tsuchiya A
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2329-35. PubMed ID: 9815631
[TBL] [Abstract][Full Text] [Related]
11. bcl-2 expression in the spectrum of preinvasive breast lesions.
Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease.
Eriksson ET; Schimmelpenning H; Aspenblad U; Zetterberg A; Auer GU
Hum Pathol; 1994 Nov; 25(11):1228-33. PubMed ID: 7959668
[TBL] [Abstract][Full Text] [Related]
13. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer.
Kang JH; Kim SJ; Noh DY; Choe KJ; Lee ES; Kang HS
J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068
[TBL] [Abstract][Full Text] [Related]
14. Expression of c-erbB3 protein in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty MK
Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
[TBL] [Abstract][Full Text] [Related]
15. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of p53 alterations throughout breast cancer progression.
Davidoff AM; Kerns BJ; Iglehart JD; Marks JR
Cancer Res; 1991 May; 51(10):2605-10. PubMed ID: 1850660
[TBL] [Abstract][Full Text] [Related]
17. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer.
Lisboa BW; Vogtländer S; Gilster T; Riethdorf L; Milde-Langosch K; Löning T
Virchows Arch; 1997 Dec; 431(6):375-81. PubMed ID: 9428925
[TBL] [Abstract][Full Text] [Related]
18. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
20. Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
Keohavong P; Gao WM; Mady HH; Kanbour-Shakir A; Melhem MF
Cancer Lett; 2004 Aug; 212(1):121-30. PubMed ID: 15246568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
